http://purl.org/np/RAFhIgZdjjKeLs0DMocZruzFNTvkRyUqfZTzIn5p9QePg#Head
http://purl.org/np/RAFhIgZdjjKeLs0DMocZruzFNTvkRyUqfZTzIn5p9QePg
http://www.nanopub.org/nschema#hasAssertion
http://purl.org/np/RAFhIgZdjjKeLs0DMocZruzFNTvkRyUqfZTzIn5p9QePg#assertion
http://purl.org/np/RAFhIgZdjjKeLs0DMocZruzFNTvkRyUqfZTzIn5p9QePg
http://www.nanopub.org/nschema#hasProvenance
http://purl.org/np/RAFhIgZdjjKeLs0DMocZruzFNTvkRyUqfZTzIn5p9QePg#provenance
http://purl.org/np/RAFhIgZdjjKeLs0DMocZruzFNTvkRyUqfZTzIn5p9QePg
http://www.nanopub.org/nschema#hasPublicationInfo
http://purl.org/np/RAFhIgZdjjKeLs0DMocZruzFNTvkRyUqfZTzIn5p9QePg#pubinfo
http://purl.org/np/RAFhIgZdjjKeLs0DMocZruzFNTvkRyUqfZTzIn5p9QePg
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.nanopub.org/nschema#Nanopublication
http://purl.org/np/RAFhIgZdjjKeLs0DMocZruzFNTvkRyUqfZTzIn5p9QePg#assertion
http://purl.obolibrary.org/obo/DOID_7148
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Disease
http://purl.org/np/RAFhIgZdjjKeLs0DMocZruzFNTvkRyUqfZTzIn5p9QePg#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#object
http://purl.obolibrary.org/obo/DOID_7148
http://purl.org/np/RAFhIgZdjjKeLs0DMocZruzFNTvkRyUqfZTzIn5p9QePg#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate
https://w3id.org/biolink/vocab/treats
http://purl.org/np/RAFhIgZdjjKeLs0DMocZruzFNTvkRyUqfZTzIn5p9QePg#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
https://identifiers.org/drugbank:DB00026
http://purl.org/np/RAFhIgZdjjKeLs0DMocZruzFNTvkRyUqfZTzIn5p9QePg#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement
http://purl.org/np/RAFhIgZdjjKeLs0DMocZruzFNTvkRyUqfZTzIn5p9QePg#association
http://www.w3.org/2000/01/rdf-schema#label
kineret is an interleukin 1 receptor antagonist indicated for rheumatoid arthritis ra reduction in signs and symptoms and slowing the progression of structural damage in moderately to severely active rheumatoid arthritis in patients 18 years of age or older who have failed 1 or more disease modifying antirheumatic drugs dmards 1 1 cryopyrin associated periodic syndromes caps treatment of neonatal onset multisystem inflammatory disease nomid 1 2 kineret is indicated for the reduction in signs and symptoms and slowing the progression of structural damage in moderately to severely active rheumatoid arthritis ra in patients 18 years of age or older who have failed 1 or more disease modifying antirheumatic drugs dmards kineret can be used alone or in combination with dmards other than tumor necrosis factor tnf blocking agents see warnings and precautions 5 2 kineret is indicated for the treatment of neonatal onset multisystem inflammatory disease nomid
http://purl.org/np/RAFhIgZdjjKeLs0DMocZruzFNTvkRyUqfZTzIn5p9QePg#association
https://w3id.org/biolink/vocab/association_type
https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation
http://purl.org/np/RAFhIgZdjjKeLs0DMocZruzFNTvkRyUqfZTzIn5p9QePg#association
https://w3id.org/biolink/vocab/provided_by
https://w3id.org/um/NeuroDKG
http://purl.org/np/RAFhIgZdjjKeLs0DMocZruzFNTvkRyUqfZTzIn5p9QePg#association
https://w3id.org/biolink/vocab/relation
https://w3id.org/um/neurodkg/SymptomaticReliefIndication
https://identifiers.org/drugbank:DB00026
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Drug
http://purl.org/np/RAFhIgZdjjKeLs0DMocZruzFNTvkRyUqfZTzIn5p9QePg#provenance
http://purl.org/np/RAFhIgZdjjKeLs0DMocZruzFNTvkRyUqfZTzIn5p9QePg#assertion
http://www.w3.org/ns/prov#wasAttributedTo
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAFhIgZdjjKeLs0DMocZruzFNTvkRyUqfZTzIn5p9QePg#pubinfo
http://purl.org/np/RAFhIgZdjjKeLs0DMocZruzFNTvkRyUqfZTzIn5p9QePg#sig
http://purl.org/nanopub/x/hasAlgorithm
RSA
http://purl.org/np/RAFhIgZdjjKeLs0DMocZruzFNTvkRyUqfZTzIn5p9QePg#sig
http://purl.org/nanopub/x/hasPublicKey
MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB
http://purl.org/np/RAFhIgZdjjKeLs0DMocZruzFNTvkRyUqfZTzIn5p9QePg#sig
http://purl.org/nanopub/x/hasSignature
TKmHDr+S1heELpvWg70G6WPxWUmYZAW5//r2s/5T/SLe4Pmzo0uhwXUnggDRnGfevQb1Ooms0+6TzRJfJHyBcgEw3l1PDXO7t9Z5pNcup7ir5Wd3sCesTpdg6KwUd4/0VDF6P5i9PTm89bFAGKAwYgGZkn98jFL/OcOshIhOajs=
http://purl.org/np/RAFhIgZdjjKeLs0DMocZruzFNTvkRyUqfZTzIn5p9QePg#sig
http://purl.org/nanopub/x/hasSignatureTarget
http://purl.org/np/RAFhIgZdjjKeLs0DMocZruzFNTvkRyUqfZTzIn5p9QePg
http://purl.org/np/RAFhIgZdjjKeLs0DMocZruzFNTvkRyUqfZTzIn5p9QePg
http://purl.org/dc/terms/created
2021-06-12T12:56:30.695+02:00
http://purl.org/np/RAFhIgZdjjKeLs0DMocZruzFNTvkRyUqfZTzIn5p9QePg
http://purl.org/dc/terms/creator
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAFhIgZdjjKeLs0DMocZruzFNTvkRyUqfZTzIn5p9QePg
https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate
http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM
http://purl.org/np/RAFhIgZdjjKeLs0DMocZruzFNTvkRyUqfZTzIn5p9QePg
https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate
http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM
http://purl.org/np/RAFhIgZdjjKeLs0DMocZruzFNTvkRyUqfZTzIn5p9QePg
https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate
http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs